Research Showing IR
Precedes Many Diseases
Peer-reviewed longitudinal evidence that undetected insulin resistance precedes clinical diagnosis by years — sometimes decades.
What the evidence collectively shows
A substantial and growing body of longitudinal research — drawn from some of the most rigorous prospective cohort studies in the world, including the Framingham Heart Study, the UK Whitehall II Study, and the Northern Manhattan Study — converges on a single conclusion: insulin resistance (IR) is not merely associated with chronic disease; in most cases it measurably precedes it, often by many years.
Across six major conditions — type 2 diabetes, hypertension, MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), stroke, asthma, and arthritis — elevated HOMA-IR scores in otherwise non-diabetic, apparently healthy individuals are consistently shown to predict clinical diagnosis years down the line. For type 2 diabetes, the lead time is the most precisely documented: insulin resistance is detectable 10 to 15 years before blood glucose rises into the diabetic range. For hypertension, prospective studies with 4–10 year follow-up periods consistently show IR doubling or tripling the risk of elevated blood pressure — independent of obesity. For stroke, an 8.5-year Northern Manhattan cohort found that high-quartile HOMA-IR nearly tripled the risk of first ischaemic stroke in non-diabetic individuals.
The critical implication for preventive health is this: by the time a condition is formally diagnosed, insulin resistance has typically been silently driving the underlying pathology for years. Conventional screening — fasting glucose, HbA1c, blood pressure measurement — captures the endpoint of this process, not its origin. HOMA-IR testing identifies the metabolic fault line long before these markers become abnormal, opening a window for genuine upstream intervention.
The conditions below are ordered by population prevalence — reflecting the scale of the public health burden each represents.
Type 2 Diabetes Mellitus
The most extensively documented relationship in metabolic medicine. IR precedes frank diabetes by 10–15 years in large population studies, with blood glucose remaining in the normal range throughout that period — making HOMA-IR the only practical early warning signal.
Hypertension
The world's leading cardiovascular risk factor, affecting over a billion people globally. Multiple longitudinal cohorts demonstrate that IR independently doubles or triples hypertension risk — even in non-obese individuals — via renal sodium retention, activation of the renin-angiotensin-aldosterone system (RAAS), and sympathetic nervous system upregulation.
MASLD — Metabolic dysfunction-Associated Steatotic Liver Disease
Now the most common chronic liver disease in the developed world, affecting an estimated 25% of adults globally. Insulin resistance is not merely associated with MASLD — it is recognised as its primary pathophysiological driver, with hepatic IR preceding and producing the fat accumulation that characterises the condition.
Stroke
Stroke is the second leading cause of death globally and a leading cause of long-term disability. The evidence for insulin resistance as an independent, upstream risk factor for ischaemic stroke — in people with no diabetes diagnosis — is now well-established across multiple prospective cohort studies.
Asthma
Emerging evidence places insulin resistance at the centre of asthma severity and progression. IR is now recognised as an independent driver of airway inflammation and exacerbation frequency — distinct from obesity alone — suggesting a metabolic dimension to asthma that conventional respiratory medicine has largely overlooked.
Arthritis (Rheumatoid)
Rheumatoid arthritis carries a markedly elevated cardiovascular risk that cannot be explained by traditional risk factors alone. Insulin resistance — driven by chronic inflammatory signalling — worsens progressively with disease duration and independently accelerates both vascular and joint damage.